Nelfinavir for COVID19: Summary of basic science data and initial clinical experience
Based on in vitro and computational model data that nelfinavir is highly active again SARS-CoV-2, we administered nelfinavir to six COVID-19 outpatients. Three of four acute outpatient COVID-19 patients became afebrile within 48 hours. In contrast, the two subacute COVID-19 patients with predominant GI symptoms responded only partially to nelfinavir.
Posted 12 May, 2020
Nelfinavir for COVID19: Summary of basic science data and initial clinical experience
Posted 12 May, 2020
Based on in vitro and computational model data that nelfinavir is highly active again SARS-CoV-2, we administered nelfinavir to six COVID-19 outpatients. Three of four acute outpatient COVID-19 patients became afebrile within 48 hours. In contrast, the two subacute COVID-19 patients with predominant GI symptoms responded only partially to nelfinavir.